Business
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
- Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically significant activity on all four key secondary efficacy endpoints - - Obexelimab was well tolerated and no new safety signals were observed - - Zenas anticipates submitting a Biologics License Application (BLA) to the FDA in the second quarter of 2026 and a Marketing Authorization Application
About this update from Zenas Biopharma, Inc.
[{"type":"image","alt":"Zenas BioPharma","displaySize":"","headline":null,"caption":"Zenas BioPharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/eefa06b05812fb9024bab85fc9c60cc1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SnwQ6A_D0E0nzqSYhAWCEQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/eefa06b05812fb9024bab85fc9c60cc1","width":300,"height":117}},"lazy":false},{"type":"text","content":"- Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare -","length":153,"tagName":"p"},{"type":"text","content":"- Obexelimab also met and demonstrated statistically significant activity on all four key secondary efficacy endpoints -","length":120,"tagName":"p"},{"type":"text","content":"- Obexelimab was well tolerated and no new safety signals were observed -","length":73,"tagName":"p"},{"type":"text","content":"- Zenas anticipates submitting a Biologics License Application (BLA) to the FDA in the second quarter of 2026 and a Marketing Authorization Application (MAA) to the EMA in the second half of 2026 -","length":197,"tagName":"p"},{"type":"text","content":"- Zenas to host a conference call today, January 5, 2026, at 8:00 a.m. ET -","length":80,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced positive results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD). Obexelimab met the primary endpoint, demonstrating a highly statistically significant and clinically meaningful 56% reduction in the risk of IgG4-RD flare compared to placebo (Hazard Ratio 0.44, p=0.0005) during the 52-week randomized placebo-controlled period. Obexelimab also met and demonstrated highly statistically significant activity compared to placebo on all four key secondary endpoints, which were reduction in investigator assessed IgG4-RD flare, the number of flares requiring rescu...